Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages - FT

The U.S. drugmaker submitted its sweetened bid, which matches Novo’s offer from Tuesday, valuing Metsera at $86.20 a share, ...

Trump announces plans to slim down cost of popular weight-loss drugs

Trump announces plans to slim down cost of popular weight-loss drugs to $149 a month - Novo Nordisk and Eli Lilly become ...
Reuters

Novo Nordisk expands lawsuits against weight-loss drug compounders

Aug 5 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, ...
FiercePharma

Novo Nordisk pads case for Wegovy in a pill as oral obesity asset nears FDA decision

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart ...